Vilin Bio Med Limited H1 FY27 revenue reaches ₹32.6 crore
Key highlights
- Vilin Bio Med reported H1 FY27 revenue of ₹32.60 crore, compared with ₹9.66 crore in H1 FY26.
- EBITDA rose 147% year on year to ₹1.80 crore from ₹0.73 crore.
- The EBITDA margin increased 330 basis points to 5.51% from 2.21%.
- Profit after tax rose to ₹1.28 crore from ₹0.15 crore in H1 FY26.
powered by IRIS

Vilin Bio Med Limited reported revenue from operations of ₹32.60 crore for the half year ended September 30, 2026, compared with ₹9.66 crore a year earlier, an increase of about 238%. Net profit rose to ₹1.28 crore from ₹0.15 crore, while EBITDA increased 147% to ₹1.80 crore.
Know Vilin Bio Med inside out
Results, valuation, peers and who's buying, in one view.
What did Vilin Bio Med report for H1 FY27?
Vilin Bio Med reported a sharp increase in revenue and profit for H1 FY27, based on its financial results for the period ended September 30, 2026. Revenue from operations was ₹32.60 crore, compared with ₹9.66 crore in H1 FY26. The increase was ₹22.94 crore, which the company presentation described as approximately 238% year-on-year growth.
EBITDA rose to ₹1.80 crore from ₹0.73 crore in the year-earlier period. Profit after tax increased to ₹1.28 crore from ₹0.15 crore. The company reported these figures in its half-year and quarter results presentation dated November 14, 2026. The reported revenue figure was stated for both standalone and consolidated results in the supplied presentation data.
How did profitability change during the period?
Vilin Bio Med's EBITDA margin improved to 5.51% in the period ended September 30, 2026, from 2.21% in the corresponding period a year earlier. That represents an expansion of 330 basis points. The rise in EBITDA was lower than the rise in revenue in percentage terms, but the margin improvement indicates that operating profit increased faster than revenue on an absolute basis.
Profit after tax was ₹1.28 crore, against ₹0.15 crore in H1 FY26. Some of the supplied result summaries present the rounded net profit growth rate as 550%, while the detailed figures and presentation state growth of 743%. The difference reflects the use of rounded figures in the summary. The underlying reported values are ₹1.28 crore and ₹0.15 crore respectively.
The comparison table provided with the results also showed revenue of ₹32.60 crore in H2 FY26, with an operating margin of 8.0% for that period. This means the H1 FY27 operating margin of 5.51% was above the year-earlier level but below the 8.0% shown for H2 FY26. The reported figures therefore show substantial year-on-year expansion, alongside a lower margin than the immediately preceding half year.
What plans has Vilin Bio Med disclosed for EBITDA growth?
Vilin Bio Med has stated in its presentation that it is targeting an EBITDA margin of 12% to 15% by FY28. The company has also disclosed a target of doubling EBITDA over the next two years through expansion of plant capacity and its product portfolio.
These are company targets rather than reported financial outcomes. The H1 FY27 EBITDA margin of 5.51% provides the current reported reference point against the FY28 margin objective. The presentation does not provide a quantified capital expenditure amount, a capacity addition figure, or a product-wise revenue outlook. Investors therefore have the stated direction and targets, but not a detailed implementation timetable in the supplied material.
The company is engaged in manufacturing and selling pharmaceutical products in India. For pharmaceutical manufacturers, capacity utilisation, product mix and the ability to absorb operating costs can influence margins. In Vilin Bio Med's case, the disclosed plan specifically links its EBITDA ambition to plant-capacity and portfolio expansion.
Got a follow-up? Ask IRIS
What corporate developments accompanied the financial results?
Vilin Bio Med's board approved the H1 FY27 standalone and consolidated financial results on November 14, 2026. The board outcome also recorded the incorporation of two subsidiaries. The supplied disclosure does not specify the business purpose, financial contribution, or expected operating impact of those subsidiaries.
Earlier in 2026, Vilin Bio Med held National Company Law Tribunal-convened meetings to consider a scheme of amalgamation with Chemgenix Laboratories. The company had also scheduled board discussions in February and September relating to other business matters, including an amalgamation proposal. The supplied information does not state that the H1 FY27 financial results incorporate a completed merger with Chemgenix Laboratories.
The company's 20th Annual General Meeting took place through video conferencing on September 2, 2026. Shareholders passed the resolutions in the AGM notice with the requisite majority, according to the scrutinizer's report. The resolutions included adoption of standalone audited financial statements for the year ended March 31, 2026, along with the board's and auditors' reports.
How do the results matter for investors and operations?
The H1 FY27 results establish a materially higher revenue and earnings base for Vilin Bio Med compared with H1 FY26. Revenue increased from ₹9.66 crore to ₹32.60 crore, and profit after tax increased from ₹0.15 crore to ₹1.28 crore. For investors, the key reported improvement is that operating margin also rose year on year, from 2.21% to 5.51%.
At the same time, the comparison with H2 FY26 shows an 8.0% operating margin, above the H1 FY27 level of 5.51%. This makes future margin execution relevant to the company's disclosed 12% to 15% FY28 target. No share-price movement, customer impact, order book, or geographic sales breakup was provided in the supplied disclosures, so those factors cannot be assessed from these results.
Shareholding data for September 2026 showed promoters held 56.65%, public shareholders held 43.22%, and foreign institutional investors held 0.13%. The number of shareholders was 384, compared with 476 in September 2025. These ownership figures provide context on the shareholder base but do not indicate how investors will respond to the results.
Conclusion
Vilin Bio Med delivered strong year-on-year growth in H1 FY27, with revenue reaching ₹32.60 crore, EBITDA rising to ₹1.80 crore and profit after tax increasing to ₹1.28 crore. The operating margin improved by 330 basis points from the year-earlier period, although it remained below the 8.0% reported for H2 FY26.
The next disclosed operating benchmark is the company's plan to double EBITDA over two years and reach a 12% to 15% EBITDA margin by FY28 through capacity and product-portfolio expansion. Investors can also watch for further disclosures on the two newly incorporated subsidiaries and the status of the proposed amalgamation with Chemgenix Laboratories.


